Is ketamine FDA-approved for bipolar depression?

No. Ketamine itself is FDA-approved only as an anesthetic. Esketamine (Spravato) is approved for treatment-resistant major depressive disorder and MDD with acute suicidal ideation, not bipolar depression. IV racemic ketamine for treatment-resistant bipolar depression is off-label, supported by Diazgranados 2010 in Archives of General Psychiatry and Zarate 2012 in Biological Psychiatry.

Will ketamine flip me into mania?

The risk of treatment-emergent mania appears low when active mood-stabilizer coverage is maintained. In Diazgranados 2010, one patient on ketamine and one on placebo developed manic-like symptoms — roughly 4.5% of ketamine exposures across the crossover, and those events were mild. We do not proceed without active mood-stabilizer treatment and direct coordination with your psychiatrist.

How is this different from your existing bipolar-depression article?

Our other article is the general overview. This one is for patients with treatment-resistant bipolar I or II depression — those who have failed multiple mood-stabilizer combinations, atypical antipsychotics like quetiapine or lurasidone, lamotrigine, and often adjunctive antidepressants. The clinical bar and the coordination requirements are higher, and the evidence base we lean on is narrower and more specific.

How fast does ketamine work in bipolar depression specifically?

Diazgranados 2010 documented antidepressant effect within 40 minutes of a single IV infusion in treatment-resistant bipolar depression — the same rapid signature seen in unipolar major depression. Zarate 2012 replicated the rapid onset. Durability is the open question; benefits often fade over days to weeks without continued mood-stabilizer treatment and a maintenance plan, which is why coordination with your psychiatrist is essential.

Ketamine for Treatment-Resistant Bipolar Depression: Diazgranados 2010 and What Came After

Q: What if I cannot tolerate lithium or valproate?

Atypical antipsychotics, lamotrigine, and other agents can serve as the mood-stabilizer foundation. The published trials used lithium or valproate, but the principle is mood-stabilizer coverage, not a specific drug. We will not move forward without that coverage in place and a treatment plan agreed to by your prescribing psychiatrist. Never stop or change medications on your own.

Why bipolar depression is the harder problem most of the time

The public picture of bipolar disorder is the manic episode—the racing speech, the impulsive decisions, the hospitalizations. But the data tell a different story about where the suffering actually lives. Long-term naturalistic studies, including the landmark NIMH Collaborative Depression Study, show that patients with bipolar I spend roughly three times as much time in depressive episodes as in manic ones, and patients with bipolar II spend almost forty times as much time depressed as hypomanic. Depression, not mania, is the dominant burden.

Bipolar depression is also where treatment options are thinnest. Standard antidepressants alone are discouraged because of the risk of switching the patient into mania or accelerating cycling. The FDA has approved only a handful of agents specifically for bipolar I depression—quetiapine, lurasidone, cariprazine, and the olanzapine-fluoxetine combination—and none of these work for everyone. Lamotrigine is widely used for bipolar maintenance and has reasonable evidence in bipolar II depression, but its onset is slow and dosing must titrate gradually because of rash risk.

The result is a population of patients who have cycled through multiple mood stabilizers, multiple atypical antipsychotics, lamotrigine, and often adjunctive antidepressants—and remain depressed. That is the population this article is for. It is not the same as our broader overview of ketamine for bipolar depression, which addresses the diagnosis as a whole. Here we are focused on what to do when the standard combinations have already failed.

Diazgranados 2010 in detail

The pivotal study is Diazgranados et al., 2010, published in Archives of General Psychiatry. The design matters, so it is worth walking through carefully. Investigators enrolled 18 patients with bipolar I or II depression who had failed at least one adequate trial of an antidepressant or mood stabilizer in the current episode, and who were maintained on therapeutic levels of lithium or valproate. Patients received a single intravenous infusion of ketamine at 0.5 mg/kg over 40 minutes, then crossed over to placebo (or the reverse) at least two weeks later. The trial was randomized, double-blind, and placebo-controlled.

The headline finding: within 40 minutes of the infusion, 9 of 16 evaluable patients (56%) achieved a 50% or greater reduction on the Montgomery-Asberg Depression Rating Scale, and 2 of 16 (13%) reached near-remission. The antidepressant signal peaked within the first day and persisted for several days in many patients before fading. Placebo response was minimal.

On safety, two patients developed manic-like symptoms during the trial—one in the ketamine arm and one in the placebo arm. Both events were mild and resolved without intervention. That works out to roughly 4.5% of ketamine exposures across the crossover producing mild hypomanic symptoms, which is within the range one might expect from background mood instability in this population. The study did not find that ketamine produced more switching than placebo in patients who were already on mood-stabilizer coverage.

Zarate 2012 and the replication

A single trial in 18 patients does not establish a treatment. The next step came from Zarate et al., 2012, published in Biological Psychiatry. This was an independent replication trial in 15 patients with treatment-resistant bipolar depression, again maintained on lithium or valproate, again using a single 0.5 mg/kg IV infusion in a randomized double-blind crossover design.

Zarate 2012 confirmed the rapid antidepressant effect, with response emerging within hours and peaking within the first day. The replication also confirmed that the rate of treatment-emergent affective switching was not meaningfully elevated in mood-stabilizer-protected patients. Both trials together gave the field its first reliable signal that the rapid-acting antidepressant property of ketamine, which had been demonstrated in unipolar major depression, generalized to the bipolar depressive state when mood-stabilizer coverage was in place.

Two NIMH-led crossover trials with overlapping methodology are not the same as a large pivotal program. They are, however, what the field has, and the consistency of the findings across the two trials is part of why bipolar depression is now widely included in the off-label evidence base for IV ketamine.

Subsequent meta-analytic evidence

In the years since, several systematic reviews have aggregated the broader literature. A 2021 systematic review by Bahji and colleagues, published in the International Journal of Neuropsychopharmacology, pooled trials of ketamine and esketamine in bipolar depression. The review concluded that the rapid antidepressant signal from Diazgranados and Zarate is consistent across small replications, that acute mania incidence remains low when patients continue mood stabilizers, and that durability and optimal maintenance cadence remain genuine open questions.

The honest summary of the meta-analytic literature is that the acute response is reproducible, the safety profile in mood-stabilizer-protected patients is acceptable, and the long-term data is thinner than anyone would like. There is no large, multi-site, long-duration randomized trial of IV racemic ketamine in treatment-resistant bipolar depression analogous to what exists for unipolar TRD.

For context, esketamine (Spravato) has FDA approval for treatment-resistant major depressive disorder and for MDD with acute suicidal ideation. It is not approved for bipolar depression. If you are weighing your options, our piece on ketamine versus Spravato walks through how the two differ. The off-label disclosure here is straightforward: ketamine is FDA-approved as an anesthetic, and its use for bipolar depression—treatment-resistant or otherwise—is off-label.

The mania question—how often, and how to manage

The single most common question we get from patients with bipolar disorder is whether ketamine will trigger mania or hypomania. The honest answer, drawn from the trial data:

The risk in mood-stabilizer-protected patients appears low. Diazgranados 2010 reported one mild manic-like episode in the ketamine arm and one in the placebo arm. Zarate 2012 reported similar findings. The rate of clinically meaningful switching has not been shown to differ from placebo when therapeutic mood-stabilizer levels are maintained.
The risk is not zero. Bipolar disorder is, by definition, a condition where mood states can shift. Any intervention that lifts depression carries some theoretical switch risk, and ketamine is no exception.
The mitigation strategy is not novel. It is the same approach psychiatrists already use when adding any antidepressant agent to a bipolar regimen: maintain active mood-stabilizer coverage, monitor for early hypomanic signs, and be prepared to adjust.

What we will not do at Music City Ketamine is treat treatment-resistant bipolar depression without active coordination with your prescribing psychiatrist. We are not a substitute for psychiatric care—we are an additional tool that fits inside an existing, mood-stabilizer-anchored treatment plan.

Mood-stabilizer coverage and the conversation with your psychiatrist

Before any infusion, three things need to be true. You need an active mood-stabilizer regimen. Your psychiatrist needs to know we are involved and agree that adjunctive ketamine is a reasonable next step. And there needs to be a plan for what happens after the acute response, because a single infusion does not solve a chronic illness.

The trials used lithium or valproate. In real-world practice, the foundation can also be an atypical antipsychotic with mood-stabilizing properties (quetiapine, lurasidone, cariprazine, olanzapine), lamotrigine, or a combination. The principle is mood-stabilizer coverage, not a specific drug. We never instruct patients to start, stop, or change any of these medications—those decisions belong to your prescribing clinician. Our job is to verify the foundation is in place and to administer the infusion safely.

Because medication interactions matter in this population, we suggest reviewing our guide to ketamine medication interactions and bringing the relevant questions to your psychiatrist. Lamotrigine, benzodiazepines, and certain anticonvulsants can affect the ketamine response in ways worth discussing in advance. If suicidal ideation is part of the clinical picture, our piece on ketamine for bipolar suicidal ideation covers what the evidence shows for that specific scenario.

What an integrated bipolar-depression plan at MCK looks like

For patients who meet the criteria—treatment-resistant bipolar I or II depression, active mood-stabilizer coverage, psychiatrist coordination—the protocol generally proceeds in three phases.

Acute induction. A short series of IV infusions at standard psychiatric dosing, typically over two to three weeks. The goal is to reproduce the rapid antidepressant signal seen in Diazgranados and Zarate, then assess whether benefit is meaningful and durable enough to justify continuation. Marla Peterson, CRNA, oversees every infusion with anesthesia-level monitoring on site, and we share infusion summaries with your psychiatrist so the broader treatment plan stays coordinated.

Stabilization. If induction produces a meaningful response, we work with your psychiatrist on a tapered maintenance schedule—less frequent infusions spaced out over weeks or months. The cadence is individual. Some patients hold a response for weeks; others need more frequent reinforcement. The literature does not yet specify an optimal interval, so the schedule is built clinically and adjusted based on what your symptoms do.

Reassessment. Every few months, your psychiatrist and our team review whether continued infusions are still earning their place in the regimen. If response durability is good, intervals widen. If not, we revisit. Ketamine is one tool in a larger plan, not the plan itself.

For patients who want to understand the broader mechanism, our piece on how ketamine works covers the NMDA-glutamate-neuroplasticity story in more detail, and our depression treatment overview places bipolar depression within the wider context of what we treat. If unipolar treatment-resistant depression is the question, our article on ketamine for treatment-resistant depression is the right starting point—the protocols overlap, but the safety considerations differ.

Honest expectations

We want to be direct about what the evidence supports and where it stops. Research suggests IV ketamine produces a rapid antidepressant response in treatment-resistant bipolar depression when mood stabilizers are continued. Studies indicate the acute mania risk in protected patients is low. Data shows the response can fade over days to weeks without continued treatment.

What the evidence does not establish: a long-term cure for bipolar depression, a replacement for mood stabilizers, an assured response for every patient, or a fixed schedule that works universally. Ketamine is FDA-approved as an anesthetic, and its use for bipolar depression is off-label. Insurance generally does not cover it for psychiatric indications. At our clinic, sessions are $475 each, and we are transparent about the financial picture before any treatment plan starts. Our piece on the FDA and ketamine covers the regulatory context in more detail.

For the right patient—treatment-resistant bipolar depression, active mood-stabilizer coverage, a psychiatrist who agrees the next step makes sense—the published evidence supports a careful trial. For the wrong patient, we will say so.